Nolvadex (Tamoxifen Citrate)

Nolvadex (tamoxifen) is employed in the management of estrogen‑driven breast cancer and in risk‑reduction strategies.

• Estrogen receptor‑positive breast cancer (adjuvant): Decreases recurrence risk after primary surgery.
• Estrogen receptor‑positive breast cancer (metastatic): Slows disease progression in advanced stages.
• High‑risk women (prevention): Lowers incidence of developing breast cancer.

• Tamoxifen acts as a competitive antagonist of estrogen receptors in breast tissue while exhibiting partial agonist activity in bone, liver and uterine tissue. By binding to the ligand‑binding domain of the estrogen receptor, it blocks estrogen‑driven transcriptional signaling that promotes tumor cell proliferation. The mixed agonist/antagonist profile also contributes to its effects on bone density and lipid metabolism.

Nolvadex may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Hot flashes: Sudden feeling of warmth, often with sweating.
• Nausea: Mild to moderate upset stomach.
• Fatigue: Generalized tiredness.
• Vaginal discharge or dryness: Changes in vaginal secretions.
• Headache: Persistent or intermittent head pain.
• Weight gain: Mild increase in body weight.

Serious or Rare Side Effects

• Deep vein thrombosis or pulmonary embolism: Blood clots in veins or lungs.
• Endometrial cancer: Uncommon malignant growth of uterine lining.
• Severe liver injury: Jaundice, elevated enzymes, or hepatic failure.

Before initiating Nolvadex, several precautionary measures should be considered to ensure safe use.

• Assess thromboembolic risk: Evaluate history of clotting disorders before therapy.
• Monitor uterine health: Perform baseline and periodic pelvic examinations for endometrial changes.
• Liver function testing: Check baseline hepatic enzymes and repeat as clinically indicated.
• Contraindications in pregnancy: Avoid use in pregnant women due to potential fetal harm.
• Drug interactions: Review concomitant medications that may affect tamoxifen metabolism.
• Store at ambient temperature: Keep below 25 °C in the original container, protected from moisture and light.

Tamoxifen can interact with several medicines, altering its effectiveness or increasing toxicity.

Major Interactions (Avoid)

• Strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine): Reduce conversion to active metabolites, decreasing efficacy.
• Estrogen‑containing hormone therapy: Counteracts tamoxifen’s anti‑estrogenic action.
• Certain anticoagulants (e.g., warfarin): May increase bleeding risk.

Moderate Interactions (Monitor Closely)

• CYP3A4 inducers (e.g., rifampin, carbamazepine): May lower tamoxifen levels.
• Selective serotonin reuptake inhibitors (other than strong CYP2D6 inhibitors): Potential additive effects on mood.
• St. John’s wort: Herbal inducer that could reduce tamoxifen exposure.